Avanos Medical, Inc. (NYSE:AVNS - Free Report) - Stock analysts at Zacks Research lowered their Q1 2025 EPS estimates for shares of Avanos Medical in a report issued on Wednesday, March 19th. Zacks Research analyst R. Department now forecasts that the company will earn $0.19 per share for the quarter, down from their previous estimate of $0.29. The consensus estimate for Avanos Medical's current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical's Q2 2025 earnings at $0.29 EPS, Q4 2025 earnings at $0.42 EPS, Q1 2026 earnings at $0.31 EPS, Q3 2026 earnings at $0.39 EPS, Q4 2026 earnings at $0.49 EPS and FY2027 earnings at $1.43 EPS.
Separately, StockNews.com raised Avanos Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th.
View Our Latest Report on AVNS
Avanos Medical Stock Down 1.7 %
Shares of NYSE AVNS traded down $0.24 during mid-day trading on Friday, reaching $14.16. The company had a trading volume of 471,883 shares, compared to its average volume of 294,886. The stock has a market capitalization of $651.40 million, a PE ratio of 41.65 and a beta of 1.17. Avanos Medical has a twelve month low of $14.25 and a twelve month high of $25.36. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. The stock's 50 day moving average is $15.80 and its 200-day moving average is $18.58.
Avanos Medical (NYSE:AVNS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.40 by $0.03. The firm had revenue of $179.60 million for the quarter, compared to analyst estimates of $177.23 million. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%.
Insider Buying and Selling
In related news, SVP Kerr Holbrook sold 7,000 shares of the firm's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the transaction, the senior vice president now directly owns 82,047 shares in the company, valued at approximately $1,251,216.75. This trade represents a 7.86 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.90% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC increased its stake in shares of Avanos Medical by 34.6% in the third quarter. FMR LLC now owns 133,844 shares of the company's stock worth $3,216,000 after purchasing an additional 34,421 shares during the period. Barclays PLC increased its position in Avanos Medical by 446.2% in the 3rd quarter. Barclays PLC now owns 96,194 shares of the company's stock worth $2,311,000 after buying an additional 78,583 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Avanos Medical by 12.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 108,470 shares of the company's stock worth $2,607,000 after buying an additional 11,613 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Avanos Medical by 6.9% during the third quarter. JPMorgan Chase & Co. now owns 69,571 shares of the company's stock worth $1,672,000 after buying an additional 4,472 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in shares of Avanos Medical by 35.8% in the third quarter. Jane Street Group LLC now owns 65,650 shares of the company's stock valued at $1,578,000 after acquiring an additional 17,306 shares during the period. Institutional investors and hedge funds own 95.17% of the company's stock.
About Avanos Medical
(
Get Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
See Also
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
